Acoustic wave cell separation is emerging as a low-shear, single-use alternative to centrifugation and membrane filtration for bioprocess harvest clarification and perfusion cell retention. Unlike conventional methods that apply mechanical force or pressure across a membrane, acoustic separation uses ultrasonic standing waves to trap cells and direct them away from the product stream without physical contact. The result is near-zero cell lysis, no fouling, and continuous operation in a fully disposable flow path.
This guide covers the physics behind acoustic cell separation, compares the commercial platforms available as of 2026, and provides a decision framework for when acoustic separation should replace or supplement centrifugation and TFF in your bioprocess.
How Acoustic Wave Cell Separation Works
Acoustic wave cell separation operates by generating an ultrasonic standing wave across a fluid channel. A piezoelectric transducer on one side of the channel emits a continuous ultrasonic wave (typically 1-3 MHz), which reflects off the opposing wall to create a pattern of alternating pressure nodes (minimum pressure amplitude) and antinodes (maximum pressure amplitude). Cells suspended in the fluid experience a primary acoustic radiation force that drives them toward the pressure nodes.
Once cells accumulate at the nodes, they form aggregates. These aggregates grow until they are large enough that gravity overcomes the buoyant force, and they sediment out of the flow channel and return to the bioreactor (in perfusion mode) or settle into a collection vessel (in harvest mode). The clarified fluid exits the channel as a cell-free product stream.
Three features distinguish acoustic separation from other clarification technologies:
- No physical barrier — unlike TFF and depth filtration, there is no membrane or filter medium to foul, clean, or replace
- No moving parts — unlike disc-stack centrifuges, there are no bearings, seals, or rotating assemblies that generate shear or require maintenance
- Continuous, single-use operation — disposable flow channels eliminate cleaning validation and cross-contamination risk between campaigns
Diagram showing a rectangular flow channel with a piezoelectric transducer on the left wall and a reflector on the right. Sinusoidal standing wave patterns are shown between the walls, with three vertical dashed lines marking pressure nodes. Red circles representing cells cluster at each node and settle downward by gravity. Blue arrows show feed flow entering from the left, and green arrows show clarified fluid exiting at the right.
The Acoustic Contrast Factor and Force Equation
The primary acoustic radiation force that drives cells toward pressure nodes is determined by the acoustic contrast factor (φ), a dimensionless quantity that depends on the density and compressibility of the cell relative to the surrounding medium. Cells with a positive acoustic contrast factor move toward pressure nodes; particles with a negative contrast factor (such as lipid droplets and gas bubbles) move toward antinodes.
The acoustic contrast factor is defined as:
Acoustic Contrast Factor
φ = (5ρp − 2ρm) / (2ρp + ρm) − βp / βm
Where ρp and ρm are the densities of the particle (cell) and medium, and βp and βm are their compressibilities.
The primary acoustic radiation force on a spherical particle is:
Fac = (4π/3) R3 k Eac φ sin(2kx)
Where R is the cell radius, k = 2π/λ is the wavenumber, Eac is the acoustic energy density, and x is the distance from the nearest pressure node.
Two features of this equation determine which cells separate efficiently:
- R3 dependence — the force scales with the cube of cell radius. A 15 μm CHO cell experiences 27 times more acoustic force than a 5 μm platelet. This makes acoustic separation highly effective for mammalian cells (10-20 μm) but impractical for bacteria (0.5-2 μm).
- φ dependence — most mammalian cells have φ values of 0.05-0.15 because they are denser and less compressible than culture medium. Dead cells with compromised membranes have lower φ values, which means acoustic separation preferentially retains viable cells.
| Cell Type | Diameter (μm) | Density (kg/m3) | Contrast Factor (φ) | Relative Force |
|---|---|---|---|---|
| CHO | 13-16 | 1,060-1,080 | 0.08-0.12 | 1.0 (reference) |
| HEK293 | 14-18 | 1,050-1,070 | 0.06-0.10 | 0.9-1.4 |
| T cells (activated) | 10-14 | 1,055-1,075 | 0.07-0.11 | 0.4-0.8 |
| Vero | 15-20 | 1,060-1,080 | 0.08-0.12 | 1.2-2.0 |
| Sf9 (insect) | 16-22 | 1,040-1,060 | 0.04-0.08 | 0.8-1.8 |
| Red blood cells | 6-8 | 1,090-1,100 | 0.12-0.18 | 0.08-0.15 |
| E. coli | 0.5-1.5 | 1,100-1,130 | 0.10-0.16 | <0.001 |
Two Modes: Harvest Clarification vs Perfusion Cell Retention
Acoustic wave separators operate in two distinct modes in bioprocessing, each with different performance requirements and operating parameters.
Harvest Clarification (Batch or Continuous)
In harvest clarification mode, the acoustic separator receives culture fluid at the end of a batch or fed-batch run and produces a clarified stream suitable for capture chromatography. The separated cells are discarded. The goal is maximum product recovery (>99%) with turbidity reduction from 2,000-5,000 NTU to below 50 NTU. Acoustic separation typically serves as a pre-clarification step before depth filtration, reducing the required depth filter area by 60-75%.
Perfusion Cell Retention (Continuous)
In perfusion mode, the acoustic separator sits in a recirculation loop between the bioreactor and the harvest line. Culture fluid is continuously pumped through the acoustic chamber, where cells are trapped and returned to the bioreactor while the cell-free permeate is collected. The key metric is cell retention efficiency, which must exceed 95% (ideally >98%) to maintain high viable cell densities of 30-60 × 106 cells/mL.
| Parameter | Harvest Clarification | Perfusion Cell Retention |
|---|---|---|
| Flow rate | 5-50 L/h per chamber | 0.5-2 bioreactor volumes/day |
| Cell density range | 5-30 × 106 cells/mL | 20-60 × 106 cells/mL |
| Target metric | >99% product recovery, <50 NTU | >95% cell retention |
| Duration | 2-8 hours | 14-60 days continuous |
| Acoustic power | 2-10 W | 1-5 W (lower to reduce heating) |
| Temperature rise | 0.5-2.0 °C | 0.3-1.0 °C (must be controlled) |
| Backflush interval | Every 30-120 s | Every 60-300 s |
Commercial Acoustic Separation Platforms Compared
Three commercial platforms dominate acoustic cell separation for bioprocessing as of 2026, each targeting different applications and throughput ranges.
Pall Cadence Acoustic Separator (CAS)
Originally developed by FloDesign Sonics and licensed to Pall, the Cadence Acoustic Separator uses multi-dimensional acoustic standing waves in a single-use flow chamber. It operates at 0-10 L/h (standard chamber) with a scale-up chamber rated at up to 50 L/h. The CAS is designed for continuous harvest clarification of CHO cell cultures at 20-50 × 106 cells/mL. It reduces depth filter area by up to 75% and can process at 0-40 °C with 0-2 barg operating pressure.
ekko Acoustic Cell Processing System (MilliporeSigma)
MilliporeSigma acquired FloDesign Sonics and developed the ekko system for cell therapy manufacturing. The ekko chamber holds approximately 100 mL and processes cells with 89 ± 3% viable cell recovery in approximately 42 minutes per run. It is a GMP-capable, automated platform with a protocol builder for concentration, washing, and media exchange of T cells, NK cells, and stem cells.
Acoustic Settlers (BioSep / Applikon)
The BioSep acoustic settler from Applikon (now Getinge) is the longest-established acoustic cell retention device, with publications dating to the 1990s. It uses a resonance chamber at 2-3 MHz to trap cells, which are returned to the bioreactor by intermittent backflush. Scale-up to 200 L/day perfusion of CHO cultures was demonstrated by Gorenflo et al. (2002), and the system maintains 95-99% retention at cell densities up to 30 × 106 cells/mL.
| Feature | Pall Cadence CAS | ekko (MilliporeSigma) | BioSep (Applikon/Getinge) |
|---|---|---|---|
| Primary application | Harvest clarification | Cell therapy processing | Perfusion cell retention |
| Throughput | 10-50 L/h | ~100 mL/run | 50-400 L/day |
| Single-use | Yes | Yes | No (reusable chamber) |
| GMP-ready | Yes | Yes | Yes (with qualification) |
| Cell viability | >98% | >89% recovery | >95% |
| Max cell density | 50 × 106/mL | ~100 × 106/mL | 30 × 106/mL |
| Automation | Manual/semi-auto | Fully automated | Manual with PLC |
| Scale-up approach | Parallel chambers | Parallel chambers | Larger chamber + parallel |
When to Choose Acoustic Separation Over Centrifugation and TFF
Acoustic cell separation does not universally replace centrifugation or TFF. It occupies a specific niche where its advantages in cell viability, single-use convenience, and continuous operation outweigh its throughput limitations. The decision depends on three factors: process scale, cell sensitivity, and operating mode.
Choose acoustic separation when:
- Cells are shear-sensitive — HEK293 for viral vector production, T cells for CAR-T, or stem cells for cell therapy lose 5-15% viability during disc-stack centrifugation. Acoustic separation maintains >98% viability.
- You need continuous, single-use clarification — for perfusion processes or intensified fed-batch with continuous harvest, acoustic separation provides uninterrupted operation without filter changes or centrifuge bowl discharges.
- Scale is below 2,000 L — at smaller scales, the capital cost advantage of centrifugation disappears, and single-use acoustic chambers are cost-competitive with depth filtration trains.
- Product is lysis-sensitive — centrifuge shear releases intracellular HCP and DNA. Acoustic separation produces harvest with 2-3-fold lower HCP and 5-10-fold lower DNA, reducing polishing burden.
Stick with centrifugation or TFF when:
- Scale exceeds 5,000 L — disc-stack centrifuges process 500-2,000 L/h, orders of magnitude beyond current acoustic throughput
- Target is microbial — bacteria (<2 μm) experience negligible acoustic radiation force; centrifugation or microfiltration is required
- Turbidity target is <5 NTU — acoustic separation alone typically achieves 20-50 NTU; a downstream depth filter or sterile filter is still needed for chromato-ready feed
How to Size an Acoustic Separator for Your Process
Sizing an acoustic separator requires matching the volumetric flow rate through the acoustic chamber to your bioreactor harvest volume and processing time. Unlike filter sizing (where capacity in L/m2 governs area), acoustic sizing is flow-rate-limited per chamber.
Worked Example: Sizing for 500 L CHO Fed-Batch Harvest
Given: 500 L bioreactor, 20 × 106 cells/mL, 85% viability, target 6-hour harvest window
Step 1: Calculate required flow rate
Q = V / t = 500 L / 6 h = 83.3 L/h
Step 2: Select chamber configuration
A single Cadence CAS scale-up chamber handles up to 50 L/h at 20 × 106 cells/mL. Two parallel chambers provide 100 L/h capacity.
Chambers needed = 83.3 / 50 = 1.67 → 2 chambers
Step 3: Verify thermal budget
At 5 W acoustic power per chamber and 83.3 L/h total flow, the temperature rise is approximately:
ΔT = P / (Q × ρ × cp) = (2 × 5) / (83.3/3600 × 1000 × 4184) ≈ 0.1 °C
This is well within the acceptable 2 °C rise for mAb stability.
Result: Two parallel Cadence CAS chambers process the 500 L harvest in 6 hours with <0.2 °C temperature rise. Downstream depth filter area can be reduced from the standard 13 m2 (at 40 L/m2) to approximately 3.5 m2 (at 150 L/m2 for pre-clarified feed).
For perfusion cell retention, sizing is based on the cell-specific perfusion rate (CSPR) and target viable cell density:
Worked Example: Acoustic Retention for 10 L Perfusion
Given: 10 L bioreactor, target 40 × 106 cells/mL, CSPR = 30 pL/cell/day
Step 1: Calculate perfusion rate
D = CSPR × VCD = 30 pL/cell/day × 40 × 106 cells/mL = 1.2 mL/mL/day = 1.2 vol/day
Q = D × V = 1.2 × 10 = 12 L/day = 0.5 L/h
Step 2: A single BioSep acoustic settler handles up to 50 L/day at this cell density with >97% retention. No scale-up needed.
Acoustic Separation in Cell Therapy Manufacturing
Cell therapy manufacturing is the application where acoustic separation adds the most value compared to conventional alternatives. Centrifugation and counterflow centrifugal elutriation (Rotea, LOVO) are the standard cell wash and concentration methods, but both expose cells to shear forces that reduce viability and functionality.
The ekko platform uses macro-scale, low-frequency standing waves to concentrate and wash T cells, NK cells, and mesenchymal stromal cells (MSCs) in a closed, single-use system. Key advantages for cell therapy include:
- Label-free separation — unlike magnetic bead-based methods (CliniMACS), acoustic separation does not introduce foreign materials that must be removed before infusion
- Viability preservation — acoustic processing maintains >98% viability for T cells compared to 90-95% for centrifugation-based washing
- Closed system — eliminates open manipulation steps that require Grade A/ISO 5 environments, potentially enabling processing in Grade C/ISO 7 cleanrooms
- Buffer exchange — achieves 2-3 log reduction of unwanted components (activation reagents, DMSO, cytokines) in a single pass
A study by Lissandrello et al. demonstrated acoustophoretic rapid media exchange and continuous-flow electrotransfection of primary human T cells, showing that acoustic processing did not alter T-cell phenotype or function while achieving concentration factors of 5-10× in a continuous flow format.
Cell Therapy Planner
Calculate cell expansion, dose requirements, and production timelines for autologous and allogeneic cell therapies.
Limitations and Current Throughput Constraints
Acoustic wave cell separation has three primary limitations that constrain its adoption in large-scale biomanufacturing as of 2026.
Throughput ceiling. The largest single acoustic chamber processes 50 L/h. A 15,000 L bioreactor harvested over 4 hours requires 3,750 L/h, which would need 75 parallel chambers. This is impractical and cost-prohibitive. At production scales above 2,000 L, disc-stack centrifugation remains the only viable primary clarification technology.
Incomplete clarification. Acoustic separation alone achieves 20-50 NTU turbidity, which is insufficient for direct loading onto capture chromatography columns (target <10 NTU). A secondary clarification step, typically depth filtration or a 0.2 μm bioburden reduction filter, is still required. Acoustic separation is therefore a pre-clarification technology that reduces, but does not eliminate, the filtration train.
Cell density dependence. Retention efficiency drops as cell density increases above 30-40 × 106 cells/mL. At 50 × 106 cells/mL, retention can fall below 90% unless the perfusion rate is reduced or additional chambers are added in parallel. This creates an inherent trade-off between cell density and perfusion rate that does not exist with membrane-based retention devices like ATF and TFF.
Despite these constraints, acoustic separation is expanding into applications where low shear and single-use operation justify the throughput trade-off. The technology is best positioned for perfusion cell retention at process development and clinical manufacturing scales (2-200 L bioreactors), cell therapy processing, and as a pre-clarification step for shear-sensitive products like viral vectors and exosomes.
Centrifugation Calculator
Calculate RCF, k-factor, and separation efficiency for disc-stack and tubular bowl centrifuges.
Frequently Asked Questions
What is acoustic wave cell separation in bioprocessing?
Acoustic wave cell separation (acoustophoresis) uses ultrasonic standing waves to trap cells at pressure nodes inside a flow channel. Cells aggregate at these nodes and sediment by gravity, separating them from the culture fluid without filters, membranes, or moving parts. The technique achieves 90-99% cell retention at perfusion rates up to 2 bioreactor volumes per day with minimal shear stress.
How does acoustic separation compare to TFF and centrifugation for harvest clarification?
Acoustic separation offers lower shear than disc-stack centrifugation and eliminates membrane fouling that limits TFF. It operates continuously in a single-use format with no moving parts and reduces depth filter area by up to 75%. However, current throughput is limited to approximately 10-50 L/h per chamber, making it best suited for volumes below 2,000 L or as a pre-clarification step before depth filtration.
What cell densities can acoustic separators handle in perfusion culture?
Acoustic separators can retain cells at densities up to 60 × 106 cells/mL for CHO cultures and 30-50 × 106 cells/mL for shear-sensitive cells like HEK293 and T cells. Retention efficiency decreases at higher densities and perfusion rates. Above 50 × 106 cells/mL, acoustic separators require reduced perfusion rates or parallel chambers to maintain greater than 95% retention.
What is the acoustic contrast factor and why does it matter?
The acoustic contrast factor (φ) determines whether cells migrate to pressure nodes (positive contrast) or antinodes (negative contrast). It depends on the density and compressibility of the cell relative to the medium. Most mammalian cells have positive acoustic contrast factors of 0.05-0.15, so they collect at pressure nodes. Cells with larger diameters experience stronger acoustic radiation forces proportional to the cube of radius, so larger cells separate more efficiently.
Is acoustic cell separation suitable for GMP manufacturing?
Yes. Several acoustic platforms are available as single-use, GMP-compatible systems. The Pall Cadence Acoustic Separator operates at up to 50 L/h for harvest clarification, and the ekko Acoustic Cell Processing System from MilliporeSigma is designed for cell therapy manufacturing with automated protocols. Both use disposable flow paths that eliminate cleaning validation requirements.
Related Tools
- Centrifugation Calculator — Calculate RCF, k-factor, sedimentation velocity, and separation efficiency for disc-stack and tubular bowl centrifuges
- Filtration Calculator — Size depth filters, sterile filters, and TFF membranes with Vmax scaling and flux models
- Cell Therapy Planner — Plan autologous and allogeneic cell therapy manufacturing with dose calculations and expansion timelines
References
- Gorenflo VM, Smith L, Dedinsky B, Persson B, Piret JM. Scale-up and optimization of an acoustic filter for 200 L/day perfusion of a CHO cell culture. Biotechnology and Bioengineering. 2002;80(4):438-444. doi:10.1002/bit.10386
- Shirgaonkar IZ, Lanthier S, Kamen A. Acoustic cell filter: a proven cell retention technology for perfusion of animal cell cultures. Biotechnology Advances. 2004;22(6):433-444. doi:10.1016/j.biotechadv.2004.03.003
- Gao Y, Wu M, Lin Y, Xu J. Acoustic microfluidic separation techniques and bioapplications: a review. Micromachines. 2020;11(10):921. doi:10.3390/mi11100921
- Fan Y, Wang X, Ren J, Lin F, Wu J. Recent advances in acoustofluidic separation technology in biology. Microsystems & Nanoengineering. 2022;8:94. doi:10.1038/s41378-022-00435-6
- Rasouli R, Martinez Villegas K, Tabrizian M. Acoustofluidics – changing paradigm in tissue engineering, therapeutics development, and biosensing. Lab on a Chip. 2023;23(5):1168-1218. doi:10.1039/D2LC00439A